Profile data is unavailable for this security.
About the company
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).
- Revenue in AUD (TTM)502.55m
- Net income in AUD5.21m
- Incorporated2017
- Employees234.00
- LocationTelix Pharmaceuticals LtdSuite 401 55 Flemington RoadNorth MelbourneMELBOURNE 3051AustraliaAUS
- Websitehttps://telixpharma.com/
Mergers & acquisitions
| Acquired company | TLX:ASX since announced | Transaction value |
|---|---|---|
| ARTMS Inc | 66.05% | 82.00m |
| IsoTherapeutics Group LLC | 80.75% | 13.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peptidream Inc | 277.86m | 24.26m | 3.42bn | 603.00 | 140.64 | 8.59 | 70.35 | 12.32 | 18.85 | 18.85 | 215.77 | 308.51 | 0.4323 | 4.20 | 5.14 | 46,391,190.00 | 3.77 | -- | 4.38 | -- | 59.16 | -- | 8.73 | -- | 3.23 | 2.59 | 0.3505 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
| Sinocelltech Group Ltd | 457.19m | -35.55m | 3.47bn | 2.33k | -- | -- | -- | 7.58 | -0.3791 | -0.3791 | 4.88 | -1.16 | 0.761 | 0.3743 | 6.86 | 930,592.90 | -5.93 | -40.17 | -15.48 | -74.63 | 96.35 | 95.42 | -7.79 | -108.20 | 0.4649 | 3.33 | 1.23 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 523.20m | 192.76m | 4.85bn | 1.04k | 25.18 | 5.33 | -- | 9.28 | 2.03 | 2.03 | 5.52 | 9.60 | 0.6091 | 3.16 | 10.51 | 2,379,802.00 | 22.44 | 0.6405 | 24.19 | 0.6933 | 94.48 | 96.42 | 36.84 | 2.54 | 8.22 | -- | 0.0004 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
| Genscript Biotech Corp | 1.28bn | -145.78m | 5.19bn | 6.94k | -- | 2.44 | -- | 4.05 | -0.3538 | -0.3538 | 3.11 | 5.12 | 0.283 | 7.59 | 5.45 | 944,745.40 | -11.97 | -18.34 | -18.27 | -26.15 | 48.78 | 54.68 | -42.30 | -64.91 | 4.65 | -- | 0.1694 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| Syngene International Ltd | 632.84m | 89.78m | 5.72bn | 6.51k | 63.93 | -- | 33.99 | 9.04 | 12.24 | 12.24 | 86.29 | -- | -- | -- | -- | 5,330,569.00 | -- | 8.62 | -- | 11.43 | 72.89 | 71.13 | 14.19 | 16.22 | -- | 6.36 | -- | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| Telix Pharmaceuticals Ltd | 502.55m | 5.21m | 6.47bn | 234.00 | 1,367.30 | 42.00 | 540.84 | 12.86 | 0.0141 | 0.0141 | 1.55 | 0.46 | 1.54 | 14.59 | 9.65 | -- | 1.59 | -29.21 | 2.54 | -40.27 | 62.56 | 61.64 | 1.04 | -37.14 | 1.32 | 24.03 | 0.1049 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 325.29m | -121.23m | 6.51bn | 1.42k | -- | 13.01 | -- | 20.01 | -2.79 | -2.79 | 7.59 | 11.47 | -- | -- | -- | 1,175,319.00 | -- | -- | -- | -- | 49.28 | -- | -37.27 | -- | 2.47 | -34.90 | 0.0251 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Akeso Inc | 955.75m | 428.29m | 6.88bn | 2.78k | 15.55 | 6.75 | 15.64 | 7.20 | 2.61 | 2.61 | 5.83 | 6.02 | 0.6168 | 0.3749 | 15.98 | 1,758,972.00 | 26.47 | -11.59 | 31.40 | -13.87 | 96.96 | -- | 42.91 | -42.49 | 4.39 | 19.18 | 0.3983 | -- | 440.35 | 337.43 | 273.60 | -- | 63.99 | -- |
| Biocon Ltd | 2.69bn | 186.47m | 8.05bn | 3.68k | 43.14 | 2.24 | 15.39 | 2.99 | 8.54 | 8.54 | 123.39 | 164.78 | 0.273 | 1.04 | 2.99 | 40,086,120.00 | 2.40 | 3.20 | 3.50 | 4.48 | 66.81 | 62.04 | 8.80 | 9.37 | 0.6595 | 1.63 | 0.3917 | 8.22 | 32.05 | 21.76 | 120.99 | 2.46 | 5.30 | 0.00 |
| WuXi Biologics (Cayman) Inc | 3.60bn | 717.88m | 8.58bn | 12.74k | 12.51 | 1.03 | 8.20 | 2.38 | 0.8439 | 0.8439 | 4.23 | 10.27 | 0.321 | 5.04 | 3.02 | 1,443,465.00 | 6.73 | 8.28 | 8.47 | 10.25 | 40.08 | 43.25 | 20.96 | 27.46 | 2.54 | -- | 0.0939 | 0.00 | 11.56 | 46.38 | -23.09 | 40.07 | 20.32 | -- |
| Holder | Shares | % Held |
|---|---|---|
| State Street Global Advisors, Australia, Ltd.as of 24 Jul 2024 | 10.24m | 3.06% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 10.06m | 3.01% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 5.21m | 1.56% |
| Vanguard Investments Australia Ltd.as of 30 Jun 2024 | 4.97m | 1.49% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 3.34m | 1.00% |
| Netwealth Investments Ltd.as of 24 Jan 2024 | 1.94m | 0.58% |
| State Street Global Advisors Trust Co.as of 24 Jul 2024 | 1.72m | 0.52% |
| BetaShares Capital Ltd.as of 28 Jun 2024 | 1.48m | 0.44% |
| AllianceBernstein LPas of 31 May 2024 | 1.22m | 0.37% |
| Portland Investment Counsel, Inc.as of 31 Mar 2024 | 1.09m | 0.33% |
